<h3>Upgrades</h3><br><p>OTR Global upgraded the previous rating for <strong>Crocs Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) from Mixed to Positive. For the fourth quarter, Crocs had an EPS of $2.65, compared to year-ago quarter EPS of $2.15. At the moment, the stock has a 52-week-high of $143.50 and a 52-week-low of $46.14. Crocs closed at $134.30 at the end of the last trading period.   </p><br><p>For <strong>HP Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>), JP Morgan upgraded the previous rating of Neutral to Overweight. For the first quarter, HP had an EPS of $0.75, compared to year-ago quarter EPS of $1.10. The stock has a 52-week-high of $40.74 and a 52-week-low of $24.08. At the end of the last trading period, HP closed at $29.82.   </p><br><p>According to Susquehanna, the prior rating for <strong>Taiwan Semiconductor Manufacturing Co Ltd</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) was changed from Neutral to Positive. For the fourth quarter, Taiwan Semiconductor had an EPS of $1.82, compared to year-ago quarter EPS of $1.15. The current stock performance of Taiwan Semiconductor shows a 52-week-high of $106.43 and a 52-week-low of $59.44. Moreover, at the end of the last trading period, the closing price was at $87.20.   </p><br><p>For <strong>Ollie's Bargain Outlet Holdings Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>), JP Morgan upgraded the previous rating of Underweight to Neutral. Ollie's Bargain Outlet earned $0.84 in the fourth quarter, compared to $0.69 in the year-ago quarter. The stock has a 52-week-high of $72.25 and a 52-week-low of $40.40. At the end of the last trading period, Ollie's Bargain Outlet closed at $57.54.   </p><br><p>According to Raymond James, the prior rating for <strong>DexCom Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) was changed from Outperform to Strong Buy. DexCom earned $0.34 in the fourth quarter, compared to $0.17 in the year-ago quarter. At the moment, the stock has a 52-week-high of $125.58 and a 52-week-low of $66.94. DexCom closed at $115.70 at the end of the last trading period.   </p><br><p>JP Morgan upgraded the previous rating for <strong>SLM Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) from Neutral to Overweight. In the fourth quarter, SLM showed an EPS of $0.33, compared to $1.05 from the year-ago quarter. The current stock performance of SLM shows a 52-week-high of $20.16 and a 52-week-low of $10.81. Moreover, at the end of the last trading period, the closing price was at $14.32.   </p><br><p>According to JP Morgan, the prior rating for <strong>Lumentum Holdings Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) was changed from Neutral to Overweight. In the second quarter, Lumentum Holdings showed an EPS of $1.52, compared to $1.60 from the year-ago quarter. At the moment, the stock has a 52-week-high of $96.45 and a 52-week-low of $44.94. Lumentum Holdings closed at $45.24 at the end of the last trading period.   </p><br><p>Piper Sandler upgraded the previous rating for <strong>Biogen Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Neutral to Overweight. Biogen earned $4.05 in the fourth quarter, compared to $3.39 in the year-ago quarter. The current stock performance of Biogen shows a 52-week-high of $311.79 and a 52-week-low of $187.22. Moreover, at the end of the last trading period, the closing price was at $288.13.   </p><br><p>Piper Sandler upgraded the previous rating for <strong>Enphase Energy Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Neutral to Overweight. In the fourth quarter, Enphase Energy showed an EPS of $1.51, compared to $0.73 from the year-ago quarter. The stock has a 52-week-high of $339.88 and a 52-week-low of $128.68. At the end of the last trading period, Enphase Energy closed at $208.90.   </p><br><p><em><a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a></em></p><br><h3>Downgrades</h3><br><p>For <strong>Prometheus Biosciences Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXDX#NASDAQ">RXDX</a>), Guggenheim downgraded the previous rating of Buy to Neutral. Prometheus Biosciences earned $0.90 in the fourth quarter, compared to $0.77 in the year-ago quarter. The current stock performance of Prometheus Biosciences shows a 52-week-high of $129.60 and a 52-week-low of $21.57. Moreover, at the end of the last trading period, the closing price was at $114.01.   </p><br><p>Oppenheimer downgraded the previous rating for <strong>EverQuote Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) from Outperform to Perform. For the fourth quarter, EverQuote had an EPS of $0.26, compared to year-ago quarter EPS of $0.29. The stock has a 52-week-high of $18.86 and a 52-week-low of $5.25. At the end of the last trading period, EverQuote closed at $8.66.   </p><br><p>For <strong>Valero Energy Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>), Tudor Pickering downgraded the previous rating of Buy to Hold. For the fourth quarter, Valero Energy had an EPS of $8.45, compared to year-ago quarter EPS of $2.47. The current stock performance of Valero Energy shows a 52-week-high of $160.16 and a 52-week-low of $96.76. Moreover, at the end of the last trading period, the closing price was at $131.86.   </p><br><p>UBS downgraded the previous rating for <strong>Cushman &amp; Wakefield PLC</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>) from Buy to Neutral. In the fourth quarter, Cushman &amp; Wakefield showed an EPS of $0.46, compared to $0.94 from the year-ago quarter. At the moment, the stock has a 52-week-high of $19.50 and a 52-week-low of $9.26. Cushman &amp; Wakefield closed at $9.51 at the end of the last trading period.   </p><br><p>For <strong>Adecoagro SA</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>), HSBC downgraded the previous rating of Buy to Hold. Adecoagro earned $0.17 in the fourth quarter, compared to $0.52 in the year-ago quarter. The current stock performance of Adecoagro shows a 52-week-high of $13.54 and a 52-week-low of $6.96. Moreover, at the end of the last trading period, the closing price was at $8.98.   </p><br><p>B of A Securities downgraded the previous rating for <strong>Westlake Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Buy to Neutral. Westlake earned $1.79 in the fourth quarter, compared to $4.98 in the year-ago quarter. The current stock performance of Westlake shows a 52-week-high of $140.99 and a 52-week-low of $81.39. Moreover, at the end of the last trading period, the closing price was at $118.12.   </p><br><p>B of A Securities downgraded the previous rating for <strong>Ecolab Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) from Neutral to Underperform. For the fourth quarter, Ecolab had an EPS of $1.27, compared to year-ago quarter EPS of $1.28. The stock has a 52-week-high of $185.50 and a 52-week-low of $131.04. At the end of the last trading period, Ecolab closed at $164.37.   </p><br><p>According to JMP Securities, the prior rating for <strong>PENN Entertainment Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) was changed from Market Outperform to Market Perform. PENN Entertainment earned $0.13 in the fourth quarter, compared to $0.26 in the year-ago quarter. The current stock performance of PENN Entertainment shows a 52-week-high of $39.89 and a 52-week-low of $25.49. Moreover, at the end of the last trading period, the closing price was at $28.71.   </p><br><p>Baird downgraded the previous rating for <strong>Catalent Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>) from Outperform to Neutral. For the second quarter, Catalent had an EPS of $0.67, compared to year-ago quarter EPS of $0.90. The stock has a 52-week-high of $115.30 and a 52-week-low of $40.70. At the end of the last trading period, Catalent closed at $46.32.   </p><br><p>BMO Capital downgraded the previous rating for <strong>Essex Property Trust Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) from Market Perform to Underperform. For the fourth quarter, Essex Property Trust had an EPS of $3.77, compared to year-ago quarter EPS of $3.25. The stock has a 52-week-high of $363.00 and a 52-week-low of $195.03. At the end of the last trading period, Essex Property Trust closed at $207.94.   </p><br><p>For <strong>Kaltura Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTR#NASDAQ">KLTR</a>), B of A Securities downgraded the previous rating of Neutral to Underperform. For the fourth quarter, Kaltura had an EPS of $0.06, compared to year-ago quarter EPS of $0.09. The stock has a 52-week-high of $2.80 and a 52-week-low of $1.33. At the end of the last trading period, Kaltura closed at $1.87.   </p><br><p>For <strong>ConocoPhillips</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), Mizuho downgraded the previous rating of Buy to Neutral. For the fourth quarter, ConocoPhillips had an EPS of $2.71, compared to year-ago quarter EPS of $2.27. At the moment, the stock has a 52-week-high of $138.46 and a 52-week-low of $78.30. ConocoPhillips closed at $108.50 at the end of the last trading period.   </p><br><p>Raymond James downgraded the previous rating for <strong>AngioDynamics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) from Strong Buy to Outperform. For the third quarter, AngioDynamics had an EPS of $0.03, compared to year-ago quarter EPS of $0.03. The current stock performance of AngioDynamics shows a 52-week-high of $24.84 and a 52-week-low of $8.60. Moreover, at the end of the last trading period, the closing price was at $9.09.   </p><br><p>For <strong>Texas Roadhouse Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>), Raymond James downgraded the previous rating of Outperform to Market Perform. In the fourth quarter, Texas Roadhouse showed an EPS of $0.89, compared to $0.76 from the year-ago quarter. The stock has a 52-week-high of $113.20 and a 52-week-low of $68.58. At the end of the last trading period, Texas Roadhouse closed at $109.89.   </p><br><p>HC Wainwright &amp; Co. downgraded the previous rating for <strong>Talaris Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALS#NASDAQ">TALS</a>) from Buy to Neutral. Talaris Therapeutics earned $0.44 in the fourth quarter, compared to $0.35 in the year-ago quarter. The current stock performance of Talaris Therapeutics shows a 52-week-high of $9.86 and a 52-week-low of $0.89. Moreover, at the end of the last trading period, the closing price was at $1.94.   </p><br><p>For <strong>Ovintiv Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>), Wells Fargo downgraded the previous rating of Overweight to Equal-Weight. Ovintiv earned $0.91 in the fourth quarter, compared to $1.25 in the year-ago quarter. The stock has a 52-week-high of $63.29 and a 52-week-low of $32.26. At the end of the last trading period, Ovintiv closed at $38.55.   </p><br><p>Jefferies downgraded the previous rating for <strong>CommScope Holding Co Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) from Buy to Hold. For the fourth quarter, CommScope Hldg Co had an EPS of $0.49, compared to year-ago quarter EPS of $0.31. At the moment, the stock has a 52-week-high of $13.73 and a 52-week-low of $5.28. CommScope Hldg Co closed at $5.33 at the end of the last trading period.   </p><br><p>According to Jefferies, the prior rating for <strong>ViewRay Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAY#NASDAQ">VRAY</a>) was changed from Buy to Hold. ViewRay earned $0.15 in the fourth quarter, compared to $0.16 in the year-ago quarter. The current stock performance of ViewRay shows a 52-week-high of $4.96 and a 52-week-low of $1.26. Moreover, at the end of the last trading period, the closing price was at $1.30.   </p><br><p>For <strong>Teradyne Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>), JP Morgan downgraded the previous rating of Neutral to Underweight. In the fourth quarter, Teradyne showed an EPS of $0.92, compared to $1.37 from the year-ago quarter. The current stock performance of Teradyne shows a 52-week-high of $117.37 and a 52-week-low of $67.81. Moreover, at the end of the last trading period, the closing price was at $100.75.   </p><br><p>For <strong>Wolfspeed Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>), JP Morgan downgraded the previous rating of Overweight to Neutral. Wolfspeed earned $0.11 in the second quarter, compared to $0.16 in the year-ago quarter. At the moment, the stock has a 52-week-high of $125.40 and a 52-week-low of $55.26. Wolfspeed closed at $56.23 at the end of the last trading period.   </p><br><p>JP Morgan downgraded the previous rating for <strong>Cepton Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) from Neutral to Underweight. In the fourth quarter, Cepton showed an EPS of $0.09, compared to $0.00 from the year-ago quarter. At the moment, the stock has a 52-week-high of $3.20 and a 52-week-low of $0.38. Cepton closed at $0.40 at the end of the last trading period.   </p><br><p>According to New Street Research, the prior rating for <strong>Meta Platforms Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) was changed from Buy to Neutral. For the fourth quarter, Meta Platforms had an EPS of $1.76, compared to year-ago quarter EPS of $3.67. The current stock performance of Meta Platforms shows a 52-week-high of $222.11 and a 52-week-low of $88.10. Moreover, at the end of the last trading period, the closing price was at $221.49.   </p><br><p>According to Wolfe Research, the prior rating for <strong>The AES Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) was changed from Outperform to Peer Perform. In the fourth quarter, AES showed an EPS of $0.49, compared to $0.45 from the year-ago quarter. At the moment, the stock has a 52-week-high of $29.87 and a 52-week-low of $18.62. AES closed at $24.86 at the end of the last trading period.   </p><br><p>JP Morgan downgraded the previous rating for <strong>Dell Technologies Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) from Overweight to Neutral. In the fourth quarter, Dell Technologies showed an EPS of $1.80, compared to $1.72 from the year-ago quarter. At the moment, the stock has a 52-week-high of $52.56 and a 52-week-low of $32.90. Dell Technologies closed at $43.28 at the end of the last trading period.   </p><br><p>According to Stifel, the prior rating for <strong>Prometheus Biosciences Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXDX#NASDAQ">RXDX</a>) was changed from Buy to Hold. For the fourth quarter, Prometheus Biosciences had an EPS of $0.90, compared to year-ago quarter EPS of $0.77. The stock has a 52-week-high of $129.60 and a 52-week-low of $21.57. At the end of the last trading period, Prometheus Biosciences closed at $114.01.   </p><br><p><em><a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a></em></p><br><h3>Initiations</h3><br><p>With a Buy rating, Craig-Hallum initiated coverage on <strong>Symbotic Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>). The price target seems to have been set at $35.00 for Symbotic. The stock has a 52-week-high of $30.29 and a 52-week-low of $8.75. At the end of the last trading period, Symbotic closed at $27.94.   </p><br><p>UBS initiated coverage on <strong>Okta Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Buy rating. The price target for Okta is set to $100.00. For the fourth quarter, Okta had an EPS of $0.30, compared to year-ago quarter EPS of $0.18. At the moment, the stock has a 52-week-high of $150.80 and a 52-week-low of $44.13. Okta closed at $74.30 at the end of the last trading period.   </p><br><p>UBS initiated coverage on <strong>Helen Of Troy Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) with a Neutral rating. The price target for Helen Of Troy is set to $99.00. Helen Of Troy earned $2.75 in the third quarter, compared to $3.72 in the year-ago quarter. The current stock performance of Helen Of Troy shows a 52-week-high of $221.52 and a 52-week-low of $83.00. Moreover, at the end of the last trading period, the closing price was at $88.86.   </p><br><p>EF Hutton initiated coverage on <strong>Opthea Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>) with a Buy rating. The price target for Opthea is set to $23.00. None </p><br><p>Wells Fargo initiated coverage on <strong>Viridian Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with an Overweight rating. The price target for Viridian Therapeutics is set to $46.00. In the fourth quarter, Viridian Therapeutics showed an EPS of $1.13, compared to $1.32 from the year-ago quarter. The stock has a 52-week-high of $39.00 and a 52-week-low of $9.47. At the end of the last trading period, Viridian Therapeutics closed at $25.20.   </p><br><p>Alliance Global Partners initiated coverage on <strong>PHX Minerals Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) with a Buy rating. The price target for PHX Minerals is set to $5.00. For the first quarter, PHX Minerals had an EPS of $0.09, compared to year-ago quarter EPS of $0.20. At the moment, the stock has a 52-week-high of $4.97 and a 52-week-low of $2.33. PHX Minerals closed at $2.81 at the end of the last trading period.   </p><br><p>B of A Securities initiated coverage on <strong>Travel+Leisure Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) with an Underperform rating. The price target for Travel+Leisure is set to $42.00. Travel+Leisure earned $1.30 in the fourth quarter, compared to $1.19 in the year-ago quarter. At the moment, the stock has a 52-week-high of $58.26 and a 52-week-low of $33.71. Travel+Leisure closed at $39.47 at the end of the last trading period.   </p><br><p>With a Neutral rating, B of A Securities initiated coverage on <strong>Hilton Grand Vacations Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>). The price target seems to have been set at $50.00 for Hilton Grand Vacations. In the fourth quarter, Hilton Grand Vacations showed an EPS of $1.01, compared to $0.86 from the year-ago quarter. The stock has a 52-week-high of $52.56 and a 52-week-low of $32.13. At the end of the last trading period, Hilton Grand Vacations closed at $46.80.   </p><br><p>William Blair initiated coverage on <strong>Autodesk Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with an Outperform rating. For the fourth quarter, Autodesk had an EPS of $1.86, compared to year-ago quarter EPS of $1.50. The current stock performance of Autodesk shows a 52-week-high of $234.99 and a 52-week-low of $163.20. Moreover, at the end of the last trading period, the closing price was at $194.66.   </p><br><p>HC Wainwright &amp; Co. initiated coverage on <strong>Rallybio Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Buy rating. The price target for Rallybio is set to $18.00. For the fourth quarter, Rallybio had an EPS of $0.46, compared to year-ago quarter EPS of $0.42. At the moment, the stock has a 52-week-high of $15.87 and a 52-week-low of $4.15. Rallybio closed at $4.31 at the end of the last trading period.   </p><br><p>Wolfe Research initiated coverage on <strong>Check Point Software Technologies Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with an Outperform rating. The price target for Check Point Software is set to $151.00. In the fourth quarter, Check Point Software showed an EPS of $2.45, compared to $2.25 from the year-ago quarter. The current stock performance of Check Point Software shows a 52-week-high of $145.12 and a 52-week-low of $107.54. Moreover, at the end of the last trading period, the closing price was at $132.41.   </p><br><p>With a Neutral rating, Piper Sandler initiated coverage on <strong>Staar Surgical Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>). The price target seems to have been set at $65.00 for Staar Surgical. Staar Surgical earned $0.14 in the fourth quarter, compared to $0.19 in the year-ago quarter. The stock has a 52-week-high of $112.23 and a 52-week-low of $46.41. At the end of the last trading period, Staar Surgical closed at $66.47.   </p><br><p>With a Market Perform rating, BMO Capital initiated coverage on <strong>Fluence Energy Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>). The price target seems to have been set at $24.00 for Fluence Energy. Fluence Energy earned $0.11 in the first quarter, compared to $0.82 in the year-ago quarter. At the moment, the stock has a 52-week-high of $26.78 and a 52-week-low of $4.96. Fluence Energy closed at $21.35 at the end of the last trading period.   </p><br><p>Goldman Sachs initiated coverage on <strong>Corsair Gaming Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>) with a Neutral rating. The price target for Corsair Gaming is set to $20.00. For the fourth quarter, Corsair Gaming had an EPS of $0.20, compared to year-ago quarter EPS of $0.35. The stock has a 52-week-high of $20.41 and a 52-week-low of $10.97. At the end of the last trading period, Corsair Gaming closed at $17.60.   </p><br><p><em><a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a></em></p><p>Copyright &#169; Benzinga. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Benzinga does not provide investment advice.</p>